litlas
Log inCreate account

Tae Min Kim

Active 1998–2026

Also published as
Tae‐Min Kim · Tae-Min Kim
275
Papers
23,625
Citations
86
h-index
233
i10-index

Citations

Citations per year for Tae Min Kim2000: 1 citations2002: 1 citations2005: 1 citations2006: 4 citations2007: 9 citations2008: 16 citations2009: 15 citations2010: 15 citations2011: 25 citations2012: 50 citations2013: 86 citations2014: 156 citations2015: 165 citations2016: 173 citations2017: 267 citations2018: 310 citations2019: 875 citations2020: 1,127 citations2021: 1,235 citations2022: 1,151 citations2023: 922 citations2024: 1,563 citations2025: 951 citations2026: 38 citations2001: no citations, so this year is not shown2003–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,065 citing papers, 22.6% of this breakdownChina: 2,144 citing papers, 15.8% of this breakdownItaly: 799 citing papers, 5.9% of this breakdownUnited Kingdom: 656 citing papers, 4.8% of this breakdownSouth Korea: 558 citing papers, 4.1% of this breakdownGermany: 556 citing papers, 4.1% of this breakdownFrance: 555 citing papers, 4.1% of this breakdownJapan: 493 citing papers, 3.6% of this breakdownSpain: 430 citing papers, 3.2% of this breakdownCanada: 383 citing papers, 2.8% of this breakdownNetherlands: 339 citing papers, 2.5% of this breakdownAustralia: 313 citing papers, 2.3% of this breakdown
0%22.6%Other 24.2%

Institutions

Fields

  • Medicine65%
  • Biochemistry, Genetics and Molecular Biology22.5%
  • Immunology and Microbiology5.2%
  • Engineering2.6%
  • Neuroscience2.4%
  • Computer Science0.7%
  • Other1.6%

Topics

  • Cancer Immunotherapy and Biomarkers7.1%
  • Lung Cancer Treatments and Mutations7%
  • Cancer Genomics and Diagnostics4%
  • Lung Cancer Research Studies3.7%
  • CAR-T cell therapy research3.5%
  • Lymphoma Diagnosis and Treatment2.5%
  • Other72.2%

Coauthors

All papers

Open in search
  1. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

    Authors: Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok, Tatyana Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David Lewis, Marjolein van der Poel, Michelle Poon, Mariana Cota Stirner, Nurgul Kilavuz, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliott, Tahamtan Ahmadi, Martin Hutchings, Pieternella J. Lugtenburg - Journal of Clinical Oncology 2022 cited by 523

  2. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Authors: Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell - The Lancet Oncology 2019 cited by 944

  3. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    Authors: Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 cited by 997

  4. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Authors: Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan, Jamie Hirata, Elicia Penuel, Joseph N. Paulson, Ji Cheng, Grace Ku, Matthew J. Matasar - Journal of Clinical Oncology 2019 cited by 772

  5. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

    Authors: Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah - The Lancet Oncology 2021 cited by 353

  6. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

    Authors: David Planchard, Benjamin Besse, Harry J.M. Groen, Sayed M.S. Hashemi, Julien Mazières, Tae Min Kim, Élisabeth Quoix, Pierre‐Jean Souquet, Fabrice Barlési, Christina S. Baik, Liza C. Villaruz, Ronan J. Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson - Journal of Thoracic Oncology 2021 cited by 269

  7. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    Authors: Jake June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong‐Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se‐Hoon Lee, Keunchil Park, Ja‐Lok Ku, Yoon Kyung Jeon, Doo Hyun Chung, Peter J. Park, Joon Kim, Tae‐Min Kim, Young Seok Ju - Journal of Clinical Oncology 2017 cited by 508

  8. A molecular portrait of microsatellite instability across multiple cancers

    Authors: Isidro Cortés‐Ciriano, Sejoon Lee, Woong‐Yang Park, Tae‐Min Kim, Peter J. Park - Nature Communications 2017 cited by 677

  9. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    Authors: Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan‐Young Ock, Byung‐Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn - Journal of Clinical Oncology 2023 cited by 164

  10. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    Authors: James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn - Journal of Clinical Oncology 2019 cited by 397

  11. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

    Authors: David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Élisabeth Quoix, Christina S. Baik, Fabrice Barlési, Tae Min Kim, Julien Mazières, Silvia Novello, James R. Rigas, Allison Upalawanna, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson - The Lancet Oncology 2016 cited by 878

  12. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

    Authors: Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang‐We Kim, James Chih‐Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, M.R. García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao Mark Lin, Minal Mehta, Pasi A. Jänne - JAMA Oncology 2021 cited by 289

  13. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

    Authors: Luis Paz‐Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee, Chia‐Chi Lin, M.J. Flor, Massimo Di Nicola, Rosa Álvarez, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, James L. Gulley, Byoung Chul Cho - Journal of Thoracic Oncology 2020 cited by 221

  14. Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers

    Authors: Hye Young Jeong, In-Hye Ham, Sung Hak Lee, Daeun Ryu, Sang-Yong Son, Sang-Uk Han, Tae-Min Kim, Hoon Hur - Clinical Cancer Research 2021 cited by 157

  15. Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Accelerate Skin Cell Proliferation

    Authors: Soo Kim, Seul Lee, Hyun‐Jung Kim, Tae Min Kim - International Journal of Molecular Sciences 2018 cited by 218

  16. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

    Authors: Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhıt Özcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar - Blood Advances 2021 cited by 177

  17. Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    Authors: Sabarish Ayyappan, Won Seog Kim, Tae Min Kim, Jan Walewski, Seok‐Goo Cho, Isidro Jarque, Elżbieta Iskierka‐Jazdzewska, Michelle Poon, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran‐Der Tan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoît Tessoulin, Jingjin Li, Melanie Ufkin, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince - Blood 2023 cited by 48

  18. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

    Authors: Alice T. Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok, Makoto Nishio, Giorgio V. Scagliotti, David R. Spigel, Stéphanie Deudon, Cheng Zheng, Serafino Pantano, Patrick Urban, Cristian Massacesi, Kalyanee Viraswami-Appanna, Enriqueta Felip - The Lancet Oncology 2017 cited by 580

  19. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    Authors: David Planchard, Tae Min Kim, Julien Mazières, Élisabeth Quoix, Gregory J. Riely, Fabrice Barlési, Pierre‐Jean Souquet, Egbert F. Smit, Harry J.M. Groen, Ronan J. Kelly, Byoung Chul Cho, Mark A. Socinski, Lini Pandite, Christine Nase, Bo Ma, Anthony M. D’Amelio, Bijoyesh Mookerjee, C. Martin Curtis, Bruce E. Johnson - The Lancet Oncology 2016 cited by 444

  20. Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

    Authors: David A. Reardon, Tae Min Kim, Jean‐Sébastien Frenel, Matteo Simonelli, Juanita Lopez, Deepa S. Subramaniam, Lillian L. Siu, Hui Wang, Suba Krishnan, Karen Stein, Christophe Massard - Cancer 2021 cited by 121

  21. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Authors: Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz‐Ares, Jaafar Bennouna, Marina Chiara Garassino, Michael Schenker, Sang‐We Kim, Jan C. Brase, Denise Bury-Maynard, Vanessa Q. Passos, Stéphanie Deudon, Bharani Dharan, Yuanbo Song, Rafael Caparica, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 74

  22. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

    Authors: So Yeon Oh, Soyeon Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo - Scientific Reports 2021 cited by 116

  23. EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

    Authors: M-j. Ahn, F. De Marinis, L. Bonanno, B.C. Cho, Tae‐Min Kim, S. Cheng, S. Novello, C. Proto, S.-W. Kim, J.S. Lee, G. Metro, J.C. Yang, W. Xu, Ryan J. Hartmaier, A. Telaranta-Keerie, L. Poole, Lecia V. Sequist - Journal of Thoracic Oncology 2022 cited by 71

  24. The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes

    Authors: Tae‐Min Kim, Peter W. Laird, Peter J. Park - Cell 2013 cited by 391